| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 0 | 320 | 70 | 0 | 0 |
| Sales Growth | -100.00% | +357.14% | unch | unch | unch |
| Net Income | -4,310 | -27,800 | -19,030 | -8,750 | -6,680 |
| Net Income Growth | +84.50% | -46.09% | -117.49% | -30.99% | +43.15% |
Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Altamira Therapeutics Ltd. is dedicated to developing therapeutics which addresses unmet medical needs. The Company is currently active in the development of RNA therapeutics for extrahepatic therapeutic targets, nasal sprays for protection against airborne viruses and allergens or the treatment of vertigo and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss. Altamira Therapeutics Ltd., formerly known as Auris Medical Holding Ltd., is headquartered in Hamilton, Bermuda.
Fiscal Year End Date: 12/31